Was MPACT commercialised? Didn’t seem to offer a major improvement - although getting any survivors beyond months and into years is a positive but the population responder improvement seems quite material for AMP945 at this early stage. They may raise ahead of q3 and see if there’s lift off so they have hedged cash needs.
Ann: Update on ACCENT Trial in Pancreatic Cancer, page-9
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
-0.005(3.70%) |
Mkt cap ! $35.64M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.5¢ | 13.0¢ | $23.48K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 328289 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.5¢ | 77366 | 3 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| ATX (ASX) Chart |